No need to tax the sick

Clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures

Yitzhak Rosen, Naomi Yachelevich, Paul Benedek, Itamar Grotto, Avishy Goldberg, Yair Morad, Hadar Marom, Nissim Ohana, Yaron Bar-Dayan

Research output: Contribution to journalArticle

Abstract

Background: Over the last few years, major health care systems have been trying to control increasing pharmaceutical expenditures by a variety of methods, such as the controversial copayment policy, as essential health expenditures were being jeopardized. Objective: To analyze the regulatory intervention of preauthorization on a rofecoxib model in the medical corps of the Israeli Defense Forces (IDF) in terms of indications for prescription, consumption, and cost. Interventions: Guidelines established by the medical services branch based on current literature and communication with diverse specialists and hospitals were implemented by a general practitioner who checked each rofecoxib prescription that was written for IDF personnel by a specialist. The intervention was initiated in November 2000 and continued until August 2001 and after the study. Design: The study was divided into two parts. The first part was a retrospective monthly, preintervention analysis of computerized medical records of IDF personnel (N = 247) for whom rofecoxib was prescribed. The second was a prospective monthly, postintervention analysis of filled-out guideline forms (N = 250) of approved rofecoxib prescriptions. Participants: Patients were IDF personnel, age 18 to 45, treated in military and civilian outpatient clinics for whom rofecoxib was prescribed. Setting: The study took place at the Medical Service Branch of the IDF between August 2000 and August 2001. Results: We demonstrated a significant decrease in average monthly consumption (43.0%) and estimated monthly expenditures (40.84%) of rofecoxib, as well as significant shifts (p < 0.001) in indications for whom rofecoxib was approved. These shifts (from pre- to postintervention) include the following: others/nonspecified (80 to 12%), known peptic disorder (7 to 32%), peptic complaints (4 to 22%), and rheumatic (8 to 19%). Conclusion: This type of intervention can be cost-effective, can provide quality care, and may be a viable alternative to the controversial and problematic copayment policy.

Original languageEnglish (US)
Pages (from-to)932-936
Number of pages5
JournalMilitary medicine
Volume169
Issue number11
DOIs
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Health Expenditures
Guidelines
Pharmaceutical Preparations
Prescriptions
Digestion
Computerized Medical Records Systems
Costs and Cost Analysis
Quality of Health Care
Ambulatory Care Facilities
rofecoxib
General Practitioners
Communication
Delivery of Health Care

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

No need to tax the sick : Clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures. / Rosen, Yitzhak; Yachelevich, Naomi; Benedek, Paul; Grotto, Itamar; Goldberg, Avishy; Morad, Yair; Marom, Hadar; Ohana, Nissim; Bar-Dayan, Yaron.

In: Military medicine, Vol. 169, No. 11, 01.01.2004, p. 932-936.

Research output: Contribution to journalArticle

Rosen, Yitzhak ; Yachelevich, Naomi ; Benedek, Paul ; Grotto, Itamar ; Goldberg, Avishy ; Morad, Yair ; Marom, Hadar ; Ohana, Nissim ; Bar-Dayan, Yaron. / No need to tax the sick : Clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures. In: Military medicine. 2004 ; Vol. 169, No. 11. pp. 932-936.
@article{a3f74b069bec400eaa65d525aa2e9d52,
title = "No need to tax the sick: Clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures",
abstract = "Background: Over the last few years, major health care systems have been trying to control increasing pharmaceutical expenditures by a variety of methods, such as the controversial copayment policy, as essential health expenditures were being jeopardized. Objective: To analyze the regulatory intervention of preauthorization on a rofecoxib model in the medical corps of the Israeli Defense Forces (IDF) in terms of indications for prescription, consumption, and cost. Interventions: Guidelines established by the medical services branch based on current literature and communication with diverse specialists and hospitals were implemented by a general practitioner who checked each rofecoxib prescription that was written for IDF personnel by a specialist. The intervention was initiated in November 2000 and continued until August 2001 and after the study. Design: The study was divided into two parts. The first part was a retrospective monthly, preintervention analysis of computerized medical records of IDF personnel (N = 247) for whom rofecoxib was prescribed. The second was a prospective monthly, postintervention analysis of filled-out guideline forms (N = 250) of approved rofecoxib prescriptions. Participants: Patients were IDF personnel, age 18 to 45, treated in military and civilian outpatient clinics for whom rofecoxib was prescribed. Setting: The study took place at the Medical Service Branch of the IDF between August 2000 and August 2001. Results: We demonstrated a significant decrease in average monthly consumption (43.0{\%}) and estimated monthly expenditures (40.84{\%}) of rofecoxib, as well as significant shifts (p < 0.001) in indications for whom rofecoxib was approved. These shifts (from pre- to postintervention) include the following: others/nonspecified (80 to 12{\%}), known peptic disorder (7 to 32{\%}), peptic complaints (4 to 22{\%}), and rheumatic (8 to 19{\%}). Conclusion: This type of intervention can be cost-effective, can provide quality care, and may be a viable alternative to the controversial and problematic copayment policy.",
author = "Yitzhak Rosen and Naomi Yachelevich and Paul Benedek and Itamar Grotto and Avishy Goldberg and Yair Morad and Hadar Marom and Nissim Ohana and Yaron Bar-Dayan",
year = "2004",
month = "1",
day = "1",
doi = "10.7205/MILMED.169.11.932",
language = "English (US)",
volume = "169",
pages = "932--936",
journal = "Military Medicine",
issn = "0026-4075",
publisher = "Association of Military Surgeons of the US",
number = "11",

}

TY - JOUR

T1 - No need to tax the sick

T2 - Clinical guidelines for rofecoxib as an alternative effective method to the copayment policy in the advent of increasing pharmaceutical expenditures

AU - Rosen, Yitzhak

AU - Yachelevich, Naomi

AU - Benedek, Paul

AU - Grotto, Itamar

AU - Goldberg, Avishy

AU - Morad, Yair

AU - Marom, Hadar

AU - Ohana, Nissim

AU - Bar-Dayan, Yaron

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Background: Over the last few years, major health care systems have been trying to control increasing pharmaceutical expenditures by a variety of methods, such as the controversial copayment policy, as essential health expenditures were being jeopardized. Objective: To analyze the regulatory intervention of preauthorization on a rofecoxib model in the medical corps of the Israeli Defense Forces (IDF) in terms of indications for prescription, consumption, and cost. Interventions: Guidelines established by the medical services branch based on current literature and communication with diverse specialists and hospitals were implemented by a general practitioner who checked each rofecoxib prescription that was written for IDF personnel by a specialist. The intervention was initiated in November 2000 and continued until August 2001 and after the study. Design: The study was divided into two parts. The first part was a retrospective monthly, preintervention analysis of computerized medical records of IDF personnel (N = 247) for whom rofecoxib was prescribed. The second was a prospective monthly, postintervention analysis of filled-out guideline forms (N = 250) of approved rofecoxib prescriptions. Participants: Patients were IDF personnel, age 18 to 45, treated in military and civilian outpatient clinics for whom rofecoxib was prescribed. Setting: The study took place at the Medical Service Branch of the IDF between August 2000 and August 2001. Results: We demonstrated a significant decrease in average monthly consumption (43.0%) and estimated monthly expenditures (40.84%) of rofecoxib, as well as significant shifts (p < 0.001) in indications for whom rofecoxib was approved. These shifts (from pre- to postintervention) include the following: others/nonspecified (80 to 12%), known peptic disorder (7 to 32%), peptic complaints (4 to 22%), and rheumatic (8 to 19%). Conclusion: This type of intervention can be cost-effective, can provide quality care, and may be a viable alternative to the controversial and problematic copayment policy.

AB - Background: Over the last few years, major health care systems have been trying to control increasing pharmaceutical expenditures by a variety of methods, such as the controversial copayment policy, as essential health expenditures were being jeopardized. Objective: To analyze the regulatory intervention of preauthorization on a rofecoxib model in the medical corps of the Israeli Defense Forces (IDF) in terms of indications for prescription, consumption, and cost. Interventions: Guidelines established by the medical services branch based on current literature and communication with diverse specialists and hospitals were implemented by a general practitioner who checked each rofecoxib prescription that was written for IDF personnel by a specialist. The intervention was initiated in November 2000 and continued until August 2001 and after the study. Design: The study was divided into two parts. The first part was a retrospective monthly, preintervention analysis of computerized medical records of IDF personnel (N = 247) for whom rofecoxib was prescribed. The second was a prospective monthly, postintervention analysis of filled-out guideline forms (N = 250) of approved rofecoxib prescriptions. Participants: Patients were IDF personnel, age 18 to 45, treated in military and civilian outpatient clinics for whom rofecoxib was prescribed. Setting: The study took place at the Medical Service Branch of the IDF between August 2000 and August 2001. Results: We demonstrated a significant decrease in average monthly consumption (43.0%) and estimated monthly expenditures (40.84%) of rofecoxib, as well as significant shifts (p < 0.001) in indications for whom rofecoxib was approved. These shifts (from pre- to postintervention) include the following: others/nonspecified (80 to 12%), known peptic disorder (7 to 32%), peptic complaints (4 to 22%), and rheumatic (8 to 19%). Conclusion: This type of intervention can be cost-effective, can provide quality care, and may be a viable alternative to the controversial and problematic copayment policy.

UR - http://www.scopus.com/inward/record.url?scp=16644399287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644399287&partnerID=8YFLogxK

U2 - 10.7205/MILMED.169.11.932

DO - 10.7205/MILMED.169.11.932

M3 - Article

VL - 169

SP - 932

EP - 936

JO - Military Medicine

JF - Military Medicine

SN - 0026-4075

IS - 11

ER -